Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
IRST153.09
Istituto Gentili S.r.l.
Metastatic colorectal cancer
1 trial -
IRST162.14
Istituto Gentili S.r.l.
Extensive-Stage Small-Cell Lung Cancer (ES SCLC)
1 trial -
IRST185.04
Istituto Gentili S.r.l.
metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)
1 trial -
IRST204.09
Istituto Gentili S.r.l.
Acute myeloid leukemia
1 trial -
ISA101b
Regeneron UK Limited
Squamous Cell Carcinoma of the Oropharynx
2 trials -
ISIS 2503
IONIS PHARMACEUTICALS INC
Pancreatic Cancer
1 trial -
ISIS EIF4E Rx
IONIS PHARMACEUTICALS INC
Non-small Cell Lung Cancer
1 trial -
ISIS EIF4E Rx
IONIS PHARMACEUTICALS INC
Castrate-Resistant Prostate Cancer
1 trial -
ITCC-054/AAML1921
Disc Medicine
Chronic Myeloid Leukemia
1 trial -
IXAZOMIB
Takeda
Follicular Lymphoma
1 trial -
Ibrutinib
Karyopharm Therapeutics Inc
Lymphoma
1 trial -
Ibrutinib 560 mg
United Therapeutics Europe Ltd
Mantle Cell Lymphoma
1 trial -
Iclusig 15 mg film-coated tablets
Ningbo Cancer Hospital
Chronic myelogenous leukemia
1 trial -
Icotinib
The First People's Hospital of Lianyungang
Non-Small Cell Lung Cancer
1 trial -
Icotinib
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
Idasanutlin
Hoffmann-La Roche
Follicular Lymphoma
1 trial -
Ifetroban Sodium
CUMBERLAND PHARMACEUTICALS INC
Malignant Solid Tumor
1 trial -
Ifinatamab Deruxtecan
Merck Sharp and Dohme
Esophageal squamous cell carcinoma
1 trial -
Ifinatamab deruxtecan
Daiichi Sankyo
Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
Ifinatamab deruxtecan
Daiichi Sankyo
Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)
1 trial -
Imgatuzumab
Centessa Pharmaceuticals plc
Cutaneous Squamous Cell Carcinoma
1 trial -
Immunological Agent
The First People's Hospital of Lianyungang
Lung Cancer Metastatic
1 trial -
Immunomodulatory DC vaccines to target prostate cancer
Shenzhen Second People's Hospital
Prostate Cancer Indications
1 trial -
Immunotherapy combined with chemotherapy
The First People's Hospital of Lianyungang
Rectal Adenocarcinoma
1 trial -
Imx-110
Immix Biopharma
Solid Tumor, Adult
1 trial -
Indibulin
Alaunos Therapeutics
Metastatic Breast Cancer
1 trial -
Induction Therapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN
1 trial -
Induction of neo-antigen specific T cells by... for Ovarian cancer
Disc Medicine
Ovarian cancer
1 trial -
Induction therapy of GP(Pomalidomide+Obinutuzumab）
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indolent Lymphoma
1 trial -
Inetetamab
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Iniparib
Sanofi Pasteur
Breast Cancer, Metastatic
1 trial -
Injection of humanized nerve growth factor (NGF) antibody
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Cancer Pain
1 trial -
Inotuzumab Ozogamicin±Donor Lymphocyte Infusion
The First People's Hospital of Lianyungang
Leukemia, Lymphocytic, Acute
1 trial -
Inotuzumab ozogamicin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Lymphocytic Leukemia
1 trial -
Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer
The George Institute
Ovarian Cancer
1 trial -
Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells
The First People's Hospital of Lianyungang
B Cell Lymphoma
1 trial -
Intermittent PD-1/PD-L1 ICI + VEGFR-TKI
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Renal Cell Carcinoma (RCC)
1 trial -
Intismeran autogene
Merck KGaA, Darmstadt, Germany
Malignant Melanoma
1 trial -
Intravenous esketamine using Dixon's up-and-down sequential method
The First People's Hospital of Lianyungang
Hepatic Neoplasm
1 trial -
Iodine-124
United Therapeutics Europe Ltd
Thyroid Cancer
1 trial -
Iomab-B
Actinium Pharmaceuticals
Non Hodgkin Lymphoma
1 trial -
Iparomlimab and Tuvonralimab Injection (QL1706)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cholangiocarcinoma
1 trial -
Iparomlimab and Tuvonralimab Injection (QL1706)
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
Iparomlimab and Tuvonralimab Injection in combination with TFOX
The First People's Hospital of Lianyungang
Gastric or Gastroesophageal Junction Adenocarcinoma
1 trial -
Iparomlimab and Tuvonralimab combined with lenvatinib and SOX
The First People's Hospital of Lianyungang
Gastric or Gastroesophageal Junction Adenocarcinoma
1 trial -
Iparomlimab/Tuvonralimab
Chinese University of Hong Kong
LOCALLY ADVANCED CERVICAL CANCERS
1 trial -
Iparomlimab/Tuvonralimab
The First People's Hospital of Lianyungang
Recurrent Ovarian Cancer
1 trial -
Ipilimumab
United Therapeutics Europe Ltd
Locally Advanced Clear Cell Renal Cell Carcinoma
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.